A Question America is Asking: Will GLP-1 Drugs ease or increase healthcare cost?
GLP-1 drugs have become one of the biggest healthcare cost stories in the US as demand for obesity and diabetes treatment keeps rising. The debate centers on medicines such as Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Zepbound and Mounjaro, which can cost more than $1,000 a month before insurance, according to list prices published by the manufacturers. What employers, insurers, and public programs are now trying to answer is whether those pharmacy costs will be offset by fewer heart problems, hospital stays, and other expensive care over time.
The cost question is now showing up in earnings calls and federal policy
In March 2024, Medicare said it would allow Part D plans to cover Wegovy for patients with obesity and established cardiovascular disease after the US Food and Drug Administration added a cardiovascular risk reduction indication, according to the Centers for Medicare & Medicaid Services. That decision gave the cost debate a clear federal marker because Medicare had long been limited in covering anti-obesity drugs.
Employers are also putting hard numbers on the issue. A 2024 survey from the Business Group on Health found 96% of large employers were concerned about the long-term cost of GLP-1 drugs, and 79% said they covered the medicines for diabetes while far fewer covered them for weight loss alone. Prime Therapeutics said in a 2024 employer analysis that GLP-1 trend lines were among the fastest-growing areas in drug spending.
What is confirmed is that spending is already moving. FAIR Health reported in 2024 that claims tied to GLP-1 medications rose sharply from 2019 through 2023, reflecting both expanded use and broader insurer attention.
The impact reaches households, job-based plans, and state budgets
For families with employer coverage, the biggest immediate effect is often out-of-pocket cost and stricter prior authorization rules. KFF reported in 2024 that coverage for GLP-1 drugs for weight loss remained uneven across private insurance, Medicaid, and Affordable Care Act marketplace plans, with major variation from one plan sponsor to another.
State and local budget officials are watching closely because Medicaid enrollment and public employee health plans can absorb fast-rising prescription costs. In North Carolina, State Treasurer Dale Folwell said in 2023 that the State Health Plan would end coverage of weight-loss drugs including GLP-1 medicines for employees, citing projected costs of about $170 million for 2024. Other states have taken different approaches, but a full 50-state coverage picture changes frequently and is not centrally updated in one public database.
What is not yet known is whether broad savings will appear quickly enough to balance those costs for most plans. Some insurers have said the member turnover problem matters because a health plan paying in 2024 may not be the same plan that benefits from fewer complications years later.
The long-term answer depends on price, adherence, and medical results
The argument for eventual savings strengthened on March 8, 2024, when the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in certain adults with cardiovascular disease and either obesity or overweight. Novo Nordisk said the approval was based on a large outcomes trial showing a 20% reduction in major adverse cardiovascular events.
At the same time, economists and pharmacy benefit managers have said the math remains difficult at current prices. ICER, the Institute for Clinical and Economic Review, said in earlier value assessments that blockbuster obesity drugs could deliver substantial health benefits but still strain the healthcare system if priced too high for mass long-term use. Adherence also matters because patients often regain weight after stopping therapy, a pattern documented in published clinical research.
For patients, that means access may keep expanding in targeted groups while coverage limits remain common elsewhere. The practical reality in 2024 is that GLP-1 drugs are likely to create higher pharmacy spending first, while any broader medical savings will depend on who qualifies, how long they stay on treatment, and what payers decide to cover.
